A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

Exclusion Criteria

• •1. Any of the following laboratory abnormalities:
• •1. Absolute neutrophil count (ANC) \<1,500 cells/mm3 (1.5 x 109/L)
• •2. Platelet count \<100,000/mm3 (100 x 109/L)
• •3. Serum creatinine \>2.5 mg/dL (221 mmol/L)
• •4. Serum SGOT/AST or SGPT/ALT \>5.0 x upper limit of normal (ULN)
• •5. Serum total bilirubin \>2.0 mg/dL (34 mmol/L)
• •2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• •3. Prior history of malignancies other than non-small cell lung cancer (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for \> or = to 1 year.
• •4. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
• •5. Pregnant or lactating females.
• •6. Prior \> or = grade 3 allergic reaction/hypersensitivity to thalidomide.
• •7. Prior \> or = grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
• •8. Prior use of lenalidomide.
• •9. Use of any standard/experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy.